Park KS and cols., 2009 |
M (17 yr) |
PHEO |
NA |
Yes |
37,5 mg/day for 7 weeks and 25 mg/day for 4 weeks |
11 |
PR* after 7 weeks (according to 18FDG uptake) followed by SD* after 11 weeks |
Jimenez C and cols., 2009 |
F (32 yr) |
PHEO (10.5 cm) |
VHL |
Yes |
50 mg/day 4 weeks on, 2 weeks off |
36 |
PR* |
Joshua AM and cols., 2009 |
M (55 yr) |
Abdominal PGL (14.4 cm) |
SDHB |
No (after six cycles) |
50/mg day 4 weeks on, 2 weeks off (before surgery); 37.5 mg/ day 4 weeks on, 2 weeks off (after surgery) |
48 |
PR after 36 weeks followed by PD after 48 weeks (+ surgery) |
|
M (28 yr) |
Abdominal PGL (7 cm) |
SDHB |
Yes |
50/mg day 4 weeks on, 2 weeks off** |
40 |
PR |
|
F (41 yr) |
PHEO (15 cm) |
Negative for SDHB, SDHD, RET and VHL |
Yes |
50 mg/day 4 weeks on, 2 weeks off** |
40 |
PR* |
Hahn NM and cols., 2009 |
F (33 yr) |
Abdominal PGL (17 cm) |
SDHB |
Yes |
50 mg/day 4 weeks on, 2 weeks off; 50 mg/day 2 weeks on, 1 week off |
16 |
PD* |
Cirillo F, 2010 |
M (37 yr) |
Abdominal PGL (17x14x9 cm) |
NA |
Yes |
50 mg/day 4 weeks on, 2 weeks off; 25 mg/day 4 weeks on, 2 weeks off; 25 mg/day 2 weeks on, 1 week off |
24 |
SD* after 15 weeks followed by PD* after 24 weeks (+ octreotide LAR) |
Zukauskaite R and cols., 2011 |
M (31 yr) |
PGL thoracic-lumbar region (10x15 cm) |
No somatic mutations |
Yes |
50 mg/day 4 weeks on, 2 weeks off |
24 |
SD* after 12 weeks followed by PD* after 24 weeks |
|
F (54 yr) |
PHEO |
Sporadic |
Yes |
50 mg/day 4 weeks on, 2 weeks off reduced up to 12.5 mg/day |
68 |
SD* after 40 weeks followed by PD* after 68 weeks |
Ayala-Ramirez M and cols., 2012 F (8); M (9) |
(33 yr) |
PHEO |
VHL |
No |
50 mg/day 4 weeks on, 2 weeks off or 37.5 mg/day continously or 37.5 mg/day 3 weeks on, 1 week off |
24 |
SD |
|
(60 yr) |
PHEO |
Sporadic |
No |
50 mg/day 4 weeks on, 2 weeks off or 37.5 mg/day continously or 37.5 mg/day 3 weeks on, 1 week off |
44 |
PR |
|
(55 yr) |
PGL |
SDHB |
No |
50 mg/day 4 weeks on, 2 weeks off or 37.5 mg/day continously or 37.5 mg/day 3 weeks on, 1 week off |
108 |
SD |
|
(20 yr) |
PGL |
SDHB |
No |
50 mg/day 4 weeks on, 2 weeks off or 37.5 mg/day continously or 37.5 mg/day 3 weeks on, 1 week off |
NA |
SD |
|
(62 yr) |
PHEO |
Sporadic |
No |
50 mg/day 4 weeks on, 2 weeks off or 37.5 mg/day continously or 37.5 mg/day 3 weeks on, 1 week off |
1.6 |
PD |
|
(14 yr) |
PHEO |
Sporadic |
No |
50 mg/day 4 weeks on, 2 weeks off or 37.5 mg/day continously or 37.5 mg/day 3 weeks on, 1 week off |
13 |
PD |
|
(47 yr) |
PHEO |
Sporadic |
No |
50 mg/day 4 weeks on, 2 weeks off or 37.5 mg/day continously or 37.5 mg/day 3 weeks on, 1 week off |
16 |
PD |
|
(40 yr) |
PHEO |
Sporadic |
No |
50 mg/day 4 weeks on, 2 weeks off or 37.5 mg/day continously or 37.5 mg/day 3 weeks on, 1 week off |
4 |
PD |
|
(57 yr) |
PGL |
SDHB |
No |
50 mg/day 4 weeks on, 2 weeks off or 37.5 mg/day continously or 37.5 mg/day 3 weeks on, 1 week off |
NA |
NA (sunitinib was stopped due to toxicity) |
|
(60 yr) |
PGL |
SDHB |
No |
50 mg/day 4 weeks on, 2 weeks off or 37.5 mg/day continously or 37.5 mg/day 3 weeks on, 1 week off |
NA |
NA (sunitinib was stopped due to toxicity) |
|
(69 yr) |
PHEO |
Sporadic |
No |
50 mg/day 4 weeks on, 2 weeks off or 37.5 mg/day continously or 37.5 mg/day 3 weeks on, 1 week off |
NA |
NA (sunitinib was stopped due to toxicity) |
|
(27 yr) |
PHEO |
SDHB |
No |
50 mg/day 4 weeks on, 2 weeks off or 37.5 mg/day continously or 37.5 mg/day 3 weeks on, 1 week off |
NA |
SD |
|
(56 yr) |
PHEO |
Sporadic |
No |
50 mg/day 4 weeks on, 2 weeks off or 37.5 mg/day continously or 37.5 mg/day 3 weeks on, 1 week off |
48 |
PR |
|
(45 yr) |
PGL |
SDHB |
No |
50 mg/day 4 weeks on, 2 weeks off or 37.5 mg/day continously or 37.5 mg/day 3 weeks on, 1 week off |
18 |
PR |
|
(40 yr) |
PGL |
SDHB |
No |
50 mg/day 4 weeks on, 2 weeks off or 37.5 mg/day continously or 37.5 mg/day 3 weeks on, 1 week off |
32 |
SD |
|
(43 yr) |
PHEO |
SDHB |
No |
50 mg/day 4 weeks on, 2 weeks off or 37.5 mg/day continously or 37.5 mg/day 3 weeks on, 1 week off |
16.4 |
PD |
|
(63 yr) |
PHEO |
Sporadic |
No |
50 mg/day 4 weeks on, 2 weeks off or 37.5 mg/day continously or 37.5 mg/day 3 weeks on, 1 week off |
8.4 |
PD |
Nemoto K and cols., 2012 |
F (41 yr) |
PHEO (10 cm) |
NA |
Yes |
50 mg/day 4 weeks on, 2 weeks off; 25 mg/day 2 weeks on, 2 weeks off |
26 |
PR |
Sun FK and cols., 2012 |
M (32 yr) |
PHEO (18 cm) |
Negative for SDHB, SDHD, RET and VHL |
Yes |
50 mg/day 4 weeks on, 2 weeks off; 37.5 mg/day 4 weeks on, 2 weeks off |
22 |
Enlargement in the necrosis area of tumor with SD* |
|
M (51 yr) |
PHEO (12.9 cm) |
Negative for SDHB, SDHD, RET and VHL |
Yes |
50 mg/day 4 weeks on, 2 weeks off |
28 |
Necrosis of the lesions at the CT scan (PR*) |
|
F (49 yr) |
PHEO (5 cm) |
Negative for SDHB, SDHD, RET and VHL |
Yes |
50 mg/day 4 weeks on, 2 weeks off |
30 |
PR* |
Prochilo T and cols., 2012 |
F (35 yr) |
Abdominal PGL |
SDHB |
Yes |
50 mg/day 4 weeks on, 2 weeks off; 37.5 mg daily 2 weeks on, 2 weeks off; 25 mg daily 2 weeks on, 1 week off |
More than 36 |
PR* after 12 weeks followed by SD* after 36 weeks and finally PD* (evaluated by 18FDG-PET) |
Hata J and cols., 2014 |
M (23 yr) |
PHEO (8.7 cm) |
NA |
Yes |
50 mg/day 4 weeks on, 2 weeks off |
20 |
SD (the authors not reported how many weeks after) followed by PD* after 20 weeks |
|
M (60 yr) |
PHEO (7.2 cm) |
NA |
Yes |
50 mg/day 4 weeks on, 2 weeks off** |
16 |
SD* (the authors not reported how many weeks after) followed by PD* after 16 weeks |
Lebowitz-Amit R and cols., 2014 |
M (51 yr) |
Abdominal PGL (6.9x5.9 x 7.1 cm) |
Negative for SDHB, SDHC, SDHD, TMEM127 and NF1 |
Yes |
50 mg/day; 37.5 mg/day; 25/37.5 mg/day alternating |
24 |
SD* |
Bourcier ME and cols., 2013 |
F (70 yr) |
Abdominal PGL |
NA |
Yes |
50 mg/day 4 weeks on, 2 weeks off |
12 |
CR |
Our case |
M (35yr) |
Abdominal PGL |
SDHB |
yes |
25 mg/day 2 weeks on, 1 week off for the of time |
101 |
PR after 12 weeks followed by SD after 32 weeks up to 54 weeks and PD after 78 weeks |